Skip to main content

Overweight and Its Relation to CHD

UNDERSTANDING CORONARY HEART DISEASE (CHD)

According to current estimates, 64.4 million Americans have one or more types of cardiovascular disease. Within cardiovascular diseases, coronary heart disease (CHD) is the single largest killer of Americans. CHD caused 502,189 deaths in the US in 2001 – about 1 in every 5. The American Heart Association estimates that 13.2 million Americans have CHD. In fact, up to half of all sudden, out-of-hospital cardiac deaths occur in people with no prior diagnosis of heart disease, and over two-thirds of heart attach sufferers have blockages in their arteries considered to be clinically “insignificant” in terms of plaque burden and percent stenosis. Until recently, it was widely held that most heart attacks were caused by a gradual build-up of atherosclerotic plaque within the arteries of the heart (“hardening of the arteries”), impedes blood flow, and eventually results in blocked blood vessels that can cause acute ischemic events such as unstable angina, heart attack, stroke, peripheral vascular disease, and a variety of other related debilitating conditions.


Source: Association for the Eradication of Heart Attack

Scientists now know that life-threatening cardiac events are very often linked to unstable, rupture-prone arterial deposits known as “vulnerable plaques.” These unstable plaques are associated with enlargement of the arterial vessel wall, and consist of soft, biologically active, thrombogenic fatty material covered by a thin fibrous cap and characterized by a large infiltration of activated macrophages, indicating a high level of inflammation. Inflammation leads to an accumulation of proteolytic enzymes, which leads to a breakdown or sudden rupture of the fibrous cap, without warning, resulting in the release or erosion of the fatty lipid core into the blood stream. Exposure to the thromboemboli cascade promotes the formation of blood clots that can cause acute ischemic events, such as unstable angina or myocardial infarction.

Researchers believe that these vulnerable plaques are responsible for 85% or more of all heart attacks, and that the same types of plaque deposits in the carotid and cerebral arteries may account for the majority of ischemic strokes.

Comments

Post a Comment

Popular posts from this blog

Monoclonal Antibody Targets, Kills Leukemia Cells

Monoclonal Antibody Targets, Kills Leukemia Cells  Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels of a cell-surface glycoprotein receptor called CD44. Principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues identified a monoclonal antibody called RG7356 that specifically targeted CD44 and was directly toxic to cancer cells, but had little effect on normal B cells. Moreover, they found RG7356 induced CLL cells that expressed the protein ZAP-70 to undergo apoptosis or programmed cell death.
1 comment
Read more

Stem Cell Treatment May Become Option to Treat Nonhealing Bone Fractures

Stem Cell Treatment May Become Option to Treat Non healing Bone Fractures Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds. The results are being presented at The Endocrine Society's 93rd Annual Meeting in Boston. A deficiency of fracture healing is a common problem affecting an estimated 600,000 people annually in North America, according to the principal investigator, Anna Spagnoli, MD, associate professor of pediatrics and biomedical engineering at the University of North Carolina at Chapel Hill. "This problem is even more serious," Spagnoli said, "in children with osteogenesis imperfecta, or brittle bone disease, and in elderly adults with osteoporosis, because their fragile bones can easily and repeatedly break, and bone graft surgical treatment is often not successful or feasible" Fractures that do not hea
Post a Comment
Read more

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with
Post a Comment
Read more